Astrazeneca
A page on organisations in our medical research coverage, part of our health reporting, alongside the 4 reports filed on it so far.
Alnylam defends silencer drugs after
Alnylam defends its RNAi drugs after AstraZeneca's heart disease trial failure, arguing they work even for patients on stabilizer therapies.
AstraZeneca, Amgen's Tezspire succeeds in
AstraZeneca and Amgen's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially expanding the label for the immunology drug.
AstraZeneca halts cancer drug trial in setback
AstraZeneca halts cancer drug trial in setback. A target trial emulation of adults with serious mental illness (SMI) found GLP-1 receptor agonists...
AstraZeneca Lung Cancer Trial Setback, Falling U.S. Drug Prices
AstraZeneca discontinues a late-stage trial for its experimental drug volrustomig, while prescription drug prices in the U.S. experience a...